Kytopen Corp, spun out of MIT, is developing platforms designed to accelerate the discovery and manufacturing of gene-modified cell therapies. Pioneering a novel and non-viral process to engineer human cells for therapeutic applications in immuno-oncology and genetic disorders, the company's primary product -- Flowfect -- combines microfluidics and automation to make the discovery process of gene-modified cell therapies easier, faster, and more cost-effective than the state-of-the art solutions. The technology is integrated with automated liquid handling systems will reduce the cost and accelerate time to market for discovering and manufacturing next-generation cell and gene therapies.
